Global Neurostimulator Device Market
Global Neurostimulator Device Market

Neurostimulator Device Comprehensive Study by Type (Deep Brain Stimulation Devices, Spinal Cord Stimulation Devices, Gastric Electric Stimulation Devices, Vagus Nerve Stimulation Devices, Sacral Nerve Stimulation Devices, Others), Application (Parkinsonís Disease, Epilepsy, Pain Management, Essential Tremor, Urinary and Fecal Incontinence, Alzheimerís, Ischemia, Others), End-Users (Hospitals and Clinics, Ambulatory Surgical Centers, Specialty Clinics) Players and Region - Global Market Outlook to 2023

Neurostimulator Device Market Segmented into XX Submarkets. | Forecast Years: 2018- 2023 | CAGR: 12.3%  

May 2019 Edition 244 Pages 200 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Neurostimulator Device Market Overview:
The neurosimulator devices are mostly used for diagnosing and treating disorders of automatic nerves system (ANS), peripheral nervous system (PNS) and central nerves system (CNS). It has several features which can pre-sense a neurological episode on-set, optimize the inter-device communication and better user interface. As the numbers of critically neurological disorders patients are increasing, that leading to growing demands of neurosimulator devices. There has been significant rise in number of people suffering from Parkinsonís disease that figure stood up to 1.2 million Americans and atleast of 65,000 new cases annually has been witnessed. It also observed that in Europe the average rate of prevalence of Dementia patients is 1.5%. The major companies are organized several treatment of neurological disorders cases in U.S. and Asia-Pacific regions. According to AMA, the Global Neurostimulator Device market is expected to see growth rate of 12.3%

Market Drivers
  • Rising Incidence Of Chronic Diseases Propelled The Neurosimulator Device Market.
  • Increase In Geriatric Population Leads to Grow The Market.

Market Trend
  • Government regulation and initiatives emphasized the market.
  • Upsurge demand of neurosimulator devices in emerging countries

Restraints
  • Side-Effects And Risk Associated With Neurosimulator Device.
  • Serious Adverse Impact Such As Hemorrhage Due To Neurosimulator Device.

Opportunities
  • Technological Advancements Such As Transdermal Neuromodulator Boost The Growth of Neurosimulator Devices.
  • Rise in Neurological Disorders Leads to Fuelled Up the Neurosimulator Devices Market.

Challenges
  • Substitutes Treatments Available for Neurological Disorders.


Competitive Landscape:
In neurosimulator device market, it has been observed that "Fit for the Future" initiatives organised by National Health Service that aims to close a projected USD 15 million deficit means that in the region of the Basildon and Brentwood Clinical Commissioning Group outside London, "patients who need hip and spinal injections, spinal cord stimulation or facet joint injections could be referred to NHS centres outside the area or forced to seek private treatment."
Some of the key players profiled in the report are Cyberonics Inc. (United States), Medtronic Inc. (Ireland), CVRx Inc. (United States), Boston Scientific Corp. (United States), St. Jude Medical Inc. (United States), Neuropace Inc. (United States), Aleva Neurotherapeutics SA(Switzerland), Bioness Inc. (United States), EnteroMedics Inc. (United States) and NeuroSigma Inc. (United States). Additionally, following companies can also be profiled that are part of our coverage like BioControl Medical (Israel), LivaNova PLC (United Kingdom) and Synapse Biomedical Inc. (United States). Considering Market by End-Users, the sub-segment i.e. Hospitals and Clinics will boost the Neurostimulator Device market.

Market Highlights:

In April 2018, Allergan plc launched a new TrueTear neurosimulator device which is beneficial in providing Drug-Free & Drop-Free Option for adult Patients Suffering from Inadequate Tear Production.

ďAccording to food and drugs administration, its encourages the sponsors of neurological devices to use the pre-submission program to help determine whether their planned studies present significant risks to patients, whether they require an Investigational Device Exemption (IDE) prior to study, or to obtain further input on what data to collect as the basis for a marketing decision for a future submission.Ē

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Neurostimulator Device market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Neurostimulator Device market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Neurosimulator Device Manufacturers, Neurosimulator Device Traders, End-Use Market Participants of Different Segments of Neurosimulator Device, Government and Research Organizations, R&D Institutions and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.
Report Objectives / Segmentation Covered
By Type
  • Deep Brain Stimulation Devices
  • Spinal Cord Stimulation Devices
  • Gastric Electric Stimulation Devices
  • Vagus Nerve Stimulation Devices
  • Sacral Nerve Stimulation Devices
  • Others
By Application
  • Parkinsonís Disease
  • Epilepsy
  • Pain Management
  • Essential Tremor
  • Urinary and Fecal Incontinence
  • Alzheimerís
  • Ischemia
  • Others
By End-Users
  • Hospitals and Clinics
  • Ambulatory Surgical Centers
  • Specialty Clinics

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Incidence Of Chronic Diseases Propelled The Neurosimulator Device Market.
      • 3.2.2. Increase In Geriatric Population Leads to Grow The Market.
    • 3.3. Market Challenges
      • 3.3.1. Substitutes Treatments Available for Neurological Disorders.
    • 3.4. Market Trends
      • 3.4.1. Government regulation and initiatives emphasized the market.
      • 3.4.2. Upsurge demand of neurosimulator devices in emerging countries
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
  • 5. Global Neurostimulator Device, by Type, Application, End-Users and Region (value and price ) (2012-2017)
    • 5.1. Introduction
    • 5.2. Global Neurostimulator Device (Price)
      • 5.2.1. Global Neurostimulator Device by: Type (Price)
  • 6. Neurostimulator Device: Manufacturers/Players Analysis
    • 6.1. Company Profile
      • 6.1.1. Cyberonics Inc. (United States)
        • 6.1.1.1. Business Overview
        • 6.1.1.2. Products/Services Offerings
        • 6.1.1.3. Financial Analysis
        • 6.1.1.4. SWOT Analysis
      • 6.1.2. Medtronic Inc. (Ireland)
        • 6.1.2.1. Business Overview
        • 6.1.2.2. Products/Services Offerings
        • 6.1.2.3. Financial Analysis
        • 6.1.2.4. SWOT Analysis
      • 6.1.3. CVRx Inc. (United States)
        • 6.1.3.1. Business Overview
        • 6.1.3.2. Products/Services Offerings
        • 6.1.3.3. Financial Analysis
        • 6.1.3.4. SWOT Analysis
      • 6.1.4. Boston Scientific Corp. (United States)
        • 6.1.4.1. Business Overview
        • 6.1.4.2. Products/Services Offerings
        • 6.1.4.3. Financial Analysis
        • 6.1.4.4. SWOT Analysis
      • 6.1.5. St. Jude Medical Inc. (United States)
        • 6.1.5.1. Business Overview
        • 6.1.5.2. Products/Services Offerings
        • 6.1.5.3. Financial Analysis
        • 6.1.5.4. SWOT Analysis
      • 6.1.6. Neuropace Inc. (United States)
        • 6.1.6.1. Business Overview
        • 6.1.6.2. Products/Services Offerings
        • 6.1.6.3. Financial Analysis
        • 6.1.6.4. SWOT Analysis
      • 6.1.7. Aleva Neurotherapeutics SA(Switzerland)
        • 6.1.7.1. Business Overview
        • 6.1.7.2. Products/Services Offerings
        • 6.1.7.3. Financial Analysis
        • 6.1.7.4. SWOT Analysis
      • 6.1.8. Bioness Inc. (United States)
        • 6.1.8.1. Business Overview
        • 6.1.8.2. Products/Services Offerings
        • 6.1.8.3. Financial Analysis
        • 6.1.8.4. SWOT Analysis
      • 6.1.9. EnteroMedics Inc. (United States)
        • 6.1.9.1. Business Overview
        • 6.1.9.2. Products/Services Offerings
        • 6.1.9.3. Financial Analysis
        • 6.1.9.4. SWOT Analysis
      • 6.1.10. NeuroSigma Inc. (United States)
        • 6.1.10.1. Business Overview
        • 6.1.10.2. Products/Services Offerings
        • 6.1.10.3. Financial Analysis
        • 6.1.10.4. SWOT Analysis
  • 7. Global Neurostimulator Device Sale, by Type, Application, End-Users and Region (value and price ) (2018-2023)
    • 7.1. Introduction
    • 7.2. Global Neurostimulator Device (Price)
      • 7.2.1. Global Neurostimulator Device by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Neurostimulator Device: by Type(USD/Units)
  • Table 2. Company Basic Information, Sales Area and Its Competitors
  • Table 3. Company Basic Information, Sales Area and Its Competitors
  • Table 4. Company Basic Information, Sales Area and Its Competitors
  • Table 5. Company Basic Information, Sales Area and Its Competitors
  • Table 6. Company Basic Information, Sales Area and Its Competitors
  • Table 7. Company Basic Information, Sales Area and Its Competitors
  • Table 8. Company Basic Information, Sales Area and Its Competitors
  • Table 9. Company Basic Information, Sales Area and Its Competitors
  • Table 10. Company Basic Information, Sales Area and Its Competitors
  • Table 11. Company Basic Information, Sales Area and Its Competitors
  • Table 12. Neurostimulator Device: by Type(USD/Units)
  • Table 13. Research Programs/Design for This Report
  • Table 14. Key Data Information from Secondary Sources
  • Table 15. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Neurostimulator Device: by Type USD/Units (2012-2017)
  • Figure 5. Cyberonics Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 6. Cyberonics Inc. (United States) Revenue: by Geography 2017
  • Figure 7. Medtronic Inc. (Ireland) Revenue, Net Income and Gross profit
  • Figure 8. Medtronic Inc. (Ireland) Revenue: by Geography 2017
  • Figure 9. CVRx Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 10. CVRx Inc. (United States) Revenue: by Geography 2017
  • Figure 11. Boston Scientific Corp. (United States) Revenue, Net Income and Gross profit
  • Figure 12. Boston Scientific Corp. (United States) Revenue: by Geography 2017
  • Figure 13. St. Jude Medical Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 14. St. Jude Medical Inc. (United States) Revenue: by Geography 2017
  • Figure 15. Neuropace Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 16. Neuropace Inc. (United States) Revenue: by Geography 2017
  • Figure 17. Aleva Neurotherapeutics SA(Switzerland) Revenue, Net Income and Gross profit
  • Figure 18. Aleva Neurotherapeutics SA(Switzerland) Revenue: by Geography 2017
  • Figure 19. Bioness Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 20. Bioness Inc. (United States) Revenue: by Geography 2017
  • Figure 21. EnteroMedics Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. EnteroMedics Inc. (United States) Revenue: by Geography 2017
  • Figure 23. NeuroSigma Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 24. NeuroSigma Inc. (United States) Revenue: by Geography 2017
  • Figure 25. Global Neurostimulator Device: by Type USD/Units (2018-2023)
Some of the key companies/manufacturers profiled in the report
  • Cyberonics Inc. (United States)
  • Medtronic Inc. (Ireland)
  • CVRx Inc. (United States)
  • Boston Scientific Corp. (United States)
  • St. Jude Medical Inc. (United States)
  • Neuropace Inc. (United States)
  • Aleva Neurotherapeutics SA(Switzerland)
  • Bioness Inc. (United States)
  • EnteroMedics Inc. (United States)
  • NeuroSigma Inc. (United States)
Additional players considered in the study are as follows:
BioControl Medical (Israel) , LivaNova PLC (United Kingdom) , Synapse Biomedical Inc. (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation